328 related articles for article (PubMed ID: 8047377)
1. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen in children with growth retardation.
Cinaz P; Hasanoglu E; Gökçora N; Dogukan S; Demir A
Mater Med Pol; 1994; 26(2):55-8. PubMed ID: 7745984
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.
Piovesan A; Terzolo M; Reimondo G; Pia A; Codegone A; Osella G; Boccuzzi A; Paccotti P; Angeli A
Horm Metab Res; 1994 May; 26(5):234-7. PubMed ID: 8076906
[TBL] [Abstract][Full Text] [Related]
4. [Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency].
Sartorio A; Conti A; Monzani M; Ferrero S; Biella O; Casati G; Faglia G
Minerva Endocrinol; 1995 Jun; 20(2):135-40. PubMed ID: 8531895
[TBL] [Abstract][Full Text] [Related]
5. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
Joffe P; Heaf JG; Jensen LT
Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
[TBL] [Abstract][Full Text] [Related]
6. 24-h profile of serum osteocalcin in growth hormone (GH) deficient patients with and without GH treatment.
Nielsen HK; Jørgensen JO; Brixen K; Møller N; Charles P; Christensen JS
Growth Regul; 1991 Dec; 1(4):153-9. PubMed ID: 1842347
[TBL] [Abstract][Full Text] [Related]
7. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age.
Lieuw-A-Fa M; Sierra RI; Specker BL
J Bone Miner Res; 1995 Jun; 10(6):849-53. PubMed ID: 7572307
[TBL] [Abstract][Full Text] [Related]
8. Serum aminoterminal propeptide of type III procollagen: a potential predictor of the response to growth hormone therapy.
Tapanainen P; Risteli L; Knip M; Käär ML; Risteli J
J Clin Endocrinol Metab; 1988 Dec; 67(6):1244-9. PubMed ID: 3192681
[TBL] [Abstract][Full Text] [Related]
9. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
[TBL] [Abstract][Full Text] [Related]
10. [The correlation between blood concentrations of somatomedin C and the auxological characteristics in short-stature subjects].
Saggese G; Cesaretti G; Cioni C; Giannessi N; Di Spigno G; Cinquanta L
Minerva Pediatr; 1991 Sep; 43(9):549-56. PubMed ID: 1758390
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
Gonc EN; Kandemir N
Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
[TBL] [Abstract][Full Text] [Related]
12. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
Gascoin-Lachambre G; Trivin C; Brauner R; Souberbielle JC
Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy.
Kubo T; Tanaka H; Inoue M; Kanzaki S; Seino Y
Bone; 1995 Oct; 17(4):397-401. PubMed ID: 8573414
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of bone turnover in children with GH deficiency treated with GH until final height.
Baroncelli GI; Bertelloni S; Ceccarelli C; Cupelli D; Saggese G
Eur J Endocrinol; 2000 Jun; 142(6):549-56. PubMed ID: 10822216
[TBL] [Abstract][Full Text] [Related]
16. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate.
Hertel NT; Stoltenberg M; Juul A; Main KM; Müller J; Nielsen CT; Lorenzen I; Skakkebaek NE
J Clin Endocrinol Metab; 1993 Apr; 76(4):924-7. PubMed ID: 8473407
[TBL] [Abstract][Full Text] [Related]
18. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
19. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy.
Tobiume H; Kanzaki S; Hida S; Ono T; Moriwake T; Yamauchi S; Tanaka H; Seino Y
J Clin Endocrinol Metab; 1997 Jul; 82(7):2056-61. PubMed ID: 9215272
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
